TD Asset Management
CBIO

TD Asset Management’s Crescent Biopharma CBIO Stock Holding History

TD Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-642
Closed -$765K – 1348
2019
Q2 		$765K Sell
642
-101
-14% -$121K ﹤0.01% 1102
2019
Q1 		$926K Sell
743
-18
-2% -$20.6K ﹤0.01% 1056
2018
Q4 		$721K Buy
761
+34
+5% +$40.9K ﹤0.01% 1138
2018
Q3 		$1.05M Buy
727
+35
+5% +$52.9K ﹤0.01% 1153
2018
Q2 		$1.12M Buy
692
+127
+22% +$218K ﹤0.01% 1106
2018
Q1 		$917K Buy
565
+315
+126% +$655K ﹤0.01% 1082
2017
Q4 		$420K Sell
250
-3
-1% -$3.97K ﹤0.01% 1218
2017
Q3 		$354K Sell
253
-71
-22% -$83.4K ﹤0.01% 1213
2017
Q2 		$362K Buy
+324
New +$268K ﹤0.01% 1238

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $718M AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return